Merck (MRK) EPS (Basic) Growth (1y) (2010 - 2026)
Merck (MRK) EPS (Basic) Growth (1y) (2010 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | -0.10% |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 284.05% |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | -130.68% |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | -92.05% |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 2.26% |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 65.24% |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | -636.10% |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | -108.11% |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | -69.49% |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | -90.87% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -130.68% |
| Mar 31, 2026 | -184.48% |
| Dec 31, 2025 | -19.94% |
| Sep 30, 2025 | 85.94% |
| Jun 30, 2025 | -18.14% |
| Mar 31, 2025 | 7.09% |
| Dec 31, 2024 | 405.99% |
| Sep 30, 2024 | -33.37% |
| Jun 30, 2024 | 191.62% |
| Mar 31, 2024 | 69.08% |
| Dec 31, 2021 | -111.28% |
| Jun 30, 2021 | -50.19% |
| Mar 31, 2021 | -86.51% |
| Dec 31, 2020 | 129.33% |
| Sep 30, 2020 | -67.17% |
| Jun 30, 2020 | -74.38% |
| Mar 31, 2020 | 14.78% |
| Dec 31, 2019 | -205.61% |
| Sep 30, 2019 | 1.36% |
| Jun 30, 2019 | 60.60% |